CFTR and cystic fibrosis: The combinations of the cystic fibrosis transmembrane conductance regulator (CFTR) correctors lumacaftor and tezacaftor with the potentiator ivacaftor were the first CFTR modulator drugs approved for the treatment of patients with cystic fibrosis (CF) homozygous for the common F508del mutation.